Bertelsmann Investments has made a significant move in the pharma technology market by acquiring EXTEDO. The acquisition, valued at an undisclosed eight-figure euro amount, strategically enhances the digital health expertise within the Bertelsmann Next portfolio.
Since its founding in 2003, EXTEDO has been part of the IABG Group until its sale to Bertelsmann. The company is a pioneer in providing software solutions and services for the life sciences sector, particularly in Regulatory Information Management (RIM) for the pharmaceutical industry. Based in the Munich area, EXTEDO helps companies comply with regulatory requirements throughout the lifecycle of medicinal products and medical devices, serving both industrial clients and public authorities.
EXTEDO’s integrated solution platform, EXTEDOpulse, optimizes regulatory business processes including document management, registration, submission, and safety management. This platform enables companies and regulatory authorities to meet global regulatory standards, reduce time-to-market for medical products, and enhance patient health and safety.
With approximately 1,000 clients in over 65 countries, including more than 35 regulatory authorities, EXTEDO has significantly contributed to the development and improvement of regulatory standards for over 25 years.
Bertelsmann Investments’ acquisition of EXTEDO is set to drive innovation in digital healthcare by leveraging synergies within the group, particularly with companies like Docuvera and ROTE LISTE. This move enhances the digital healthcare expertise within the Bertelsmann Next portfolio, which focuses on the entrepreneurial development of new growth sectors, including digital health. To date, Bertelsmann Investments has invested around €1.7 billion in over 400 innovative companies and funds, demonstrating its commitment to innovation across various sectors.
This strategic acquisition underscores Bertelsmann Investments' ability to identify and nurture high-potential ventures in the digital health space, reflecting its strategic foresight into the expanding opportunities in the European healthcare market. By incorporating EXTEDO’s RIM expertise, Bertelsmann Investments is well-positioned to advance in the pharma tech sector, promising improved efficiencies and innovative solutions for the global life sciences ecosystem.
For more than 12 years, ConAlliance has been a leading M&A advisory firm in the healthcare sector, offering comprehensive support in company sales and acquisitions. Since its inception, the firm has successfully completed over 150 mandates, highlighting its outstanding expertise and track record. ConAlliance specializes in transactions within the global healthcare and life sciences industry, with a particular focus on healthcare IT.
To best serve healthcare IT clients, ConAlliance has developed specialized teams with expertise in both traditional investment banking and M&A practices, as well as a detailed understanding of healthcare IT niches. These teams possess specific skills and qualifications, including:
This specialized knowledge allows ConAlliance to provide clients with tailored solutions to navigate the complex landscape of healthcare M&A.